$CLYM

2022 Q4 Form 10-Q Financial Statement

#000095017022024611 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.627M $4.490M $3.394M
YoY Change 21.0% 32.29% 987.82%
% of Gross Profit
Research & Development $4.927M $4.258M $5.704M
YoY Change -28.38% -25.35% 195.54%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $9.554M $8.748M $9.383M
YoY Change -10.74% -6.77% 315.36%
Operating Profit -$8.748M -$9.383M
YoY Change -6.77% 315.36%
Interest Expense $1.032M -$1.317M -$252.0K
YoY Change 953.06% 422.62% -25300.0%
% of Operating Profit
Other Income/Expense, Net $760.0K -$934.0K -$232.0K
YoY Change 1166.67% 302.59% -23300.0%
Pretax Income -$7.762M -$9.682M -$9.615M
YoY Change -26.39% 0.7% 325.82%
Income Tax
% Of Pretax Income
Net Earnings -$7.762M -$9.682M -$9.615M
YoY Change -26.39% 0.7% 325.82%
Net Earnings / Revenue
Basic Earnings Per Share -$0.37 -$0.70
Diluted Earnings Per Share -$0.29 -$0.37 -$616.9K
COMMON SHARES
Basic Shares Outstanding 26.57M 26.57M 26.55M
Diluted Shares Outstanding 26.34M 15.59M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $123.6M $122.6M $146.0M
YoY Change -9.46% -16.02%
Cash & Equivalents $43.59M $35.94M $62.82M
Short-Term Investments $79.98M $86.68M $83.20M
Other Short-Term Assets $10.83M $10.55M $12.61M
YoY Change -8.03% -16.35%
Inventory
Prepaid Expenses $1.330M $1.898M $1.960M
Receivables
Other Receivables
Total Short-Term Assets $134.4M $133.2M $158.6M
YoY Change -9.35% -16.05%
LONG-TERM ASSETS
Property, Plant & Equipment $471.0K $585.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $128.0K $141.0K $0.00
YoY Change 82.86%
Total Long-Term Assets $599.0K $7.687M $23.62M
YoY Change -97.6% -67.45%
TOTAL ASSETS
Total Short-Term Assets $134.4M $133.2M $158.6M
Total Long-Term Assets $599.0K $7.687M $23.62M
Total Assets $135.0M $140.9M $182.3M
YoY Change -22.08% -22.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $750.0K $1.494M $2.579M
YoY Change -46.58% -42.07%
Accrued Expenses $5.047M $4.434M $2.979M
YoY Change 10.0% 48.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.097M $6.280M $5.590M
YoY Change 1.09% 12.34%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.097M $6.280M $5.590M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $6.277M $6.499M $5.590M
YoY Change 3.96% 16.26%
SHAREHOLDERS EQUITY
Retained Earnings -$120.9M -$113.1M -$65.10M
YoY Change 59.89% 73.73%
Common Stock $249.9M $248.0M $241.8M
YoY Change 2.88% 2.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $128.7M $134.4M $176.7M
YoY Change
Total Liabilities & Shareholders Equity $135.0M $140.9M $182.3M
YoY Change -22.08% -22.71%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$7.762M -$9.682M -$9.615M
YoY Change -26.39% 0.7% 325.82%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$8.449M -$4.175M -$12.97M
YoY Change 7.17% -67.8% 110.88%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $14.28M $8.509M -$106.9M
YoY Change -277.34% -107.96%
Cash From Investing Activities $14.28M $8.509M -$106.9M
YoY Change -277.34% -107.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 83.14M
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -8.449M -4.175M -12.97M
Cash From Investing Activities 14.28M 8.509M -106.9M
Cash From Financing Activities 0.000 0.000 83.14M
Net Change In Cash 5.829M 4.334M -36.74M
YoY Change -136.67% -111.8% 497.53%
FREE CASH FLOW
Cash From Operating Activities -$8.449M -$4.175M -$12.97M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei City Area Code
CityAreaCode
425
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
elym Conversion Of Redeemable Convertible Preferred Stock To Common Stock
ConversionOfRedeemableConvertiblePreferredStockToCommonStock
dei Entity Central Index Key
EntityCentralIndexKey
0001768446
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40708
dei Entity Registrant Name
EntityRegistrantName
ELIEM THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2273741
dei Entity Address Address Line1
EntityAddressAddressLine1
23515 NE Novelty Hill Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite B221 #125
dei Entity Address City Or Town
EntityAddressCityOrTown
Redmond
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98053
dei Local Phone Number
LocalPhoneNumber
276-2300
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ELYM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26567681
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35944000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46922000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
86675000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
89558000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10552000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11772000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
133171000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
148252000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
585000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2022Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
6961000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
24919000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
141000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
70000
CY2022Q3 us-gaap Assets
Assets
140858000
CY2021Q4 us-gaap Assets
Assets
173241000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1494000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1404000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4434000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4627000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
352000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6280000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6031000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
219000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q3 us-gaap Liabilities
Liabilities
6499000
CY2021Q4 us-gaap Liabilities
Liabilities
6038000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26567681
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26567681
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26567681
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26567681
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
248035000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
242939000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-581000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-123000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-113098000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-75616000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
134359000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
167203000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
140858000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
173241000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4258000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5989000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21287000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16443000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4490000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3394000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14294000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8526000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
8748000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
9383000
us-gaap Operating Expenses
OperatingExpenses
35581000
us-gaap Operating Expenses
OperatingExpenses
24969000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8748000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9383000
us-gaap Operating Income Loss
OperatingIncomeLoss
-35581000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24969000
CY2022Q3 elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
0
CY2021Q3 elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
0
elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
0
elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
11718000
CY2022Q3 us-gaap Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
1317000
CY2021Q3 us-gaap Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
252000
us-gaap Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
2516000
us-gaap Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
268000
CY2022Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
383000
CY2021Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
20000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
615000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
20000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-934000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-232000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1901000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11966000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-9682000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9615000
us-gaap Net Income Loss
NetIncomeLoss
-37482000
us-gaap Net Income Loss
NetIncomeLoss
-36935000
CY2022Q3 elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
0
CY2021Q3 elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
1322000
elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
0
elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
4548000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9682000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10937000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37482000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41483000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.49
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26336029
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26336029
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15585611
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15585611
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26290868
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26290868
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7554300
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7554300
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-9682000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9615000
us-gaap Net Income Loss
NetIncomeLoss
-37482000
us-gaap Net Income Loss
NetIncomeLoss
-36935000
CY2022Q3 elym Income Tax
IncomeTax
0
CY2021Q3 elym Income Tax
IncomeTax
0
elym Income Tax
IncomeTax
0
elym Income Tax
IncomeTax
0
CY2022Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
23000
CY2021Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
18000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-458000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-18000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9659000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9633000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37940000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36953000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
167203000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1541000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-398000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-13204000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
155142000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1772000
elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
0
us-gaap Operating Lease Expense
OperatingLeaseExpense
0
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-83000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-14596000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
142235000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1783000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
23000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-9682000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
134359000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-24983000
CY2021Q1 elym Exercise Of Stock Options And Release Of Restricted Stock Awards
ExerciseOfStockOptionsAndReleaseOfRestrictedStockAwards
105000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
297000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-18601000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-43182000
CY2021Q2 elym Exercise Of Stock Options And Release Of Restricted Stock Awards
ExerciseOfStockOptionsAndReleaseOfRestrictedStockAwards
6000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1050000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-8719000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-50845000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
83144000
CY2021Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
152759000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1236000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-18000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-9615000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
176661000
us-gaap Profit Loss
ProfitLoss
-37482000
us-gaap Profit Loss
ProfitLoss
-36935000
us-gaap Share Based Compensation
ShareBasedCompensation
5096000
us-gaap Share Based Compensation
ShareBasedCompensation
2583000
us-gaap Operating Lease Expense
OperatingLeaseExpense
329000
elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
11718000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-223000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-83000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2220000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
245000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-1219000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
11103000
elym Increase Decrease In Non Current Assets
IncreaseDecreaseInNonCurrentAssets
72000
elym Increase Decrease In Non Current Assets
IncreaseDecreaseInNonCurrentAssets
2633000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
91000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1287000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-188000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1791000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-356000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28920000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28188000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
81249000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
106919000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
101411000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20162000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-106919000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
83144000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
0
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
93939000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
111000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
177194000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2220000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
245000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10978000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
42332000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46922000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20487000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35944000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62819000
elym Conversion Of Redeemable Convertible Preferred Stock To Common Stock
ConversionOfRedeemableConvertiblePreferredStockToCommonStock
152759000
elym Cash Paid For Leases Included In Operating Cash Outflows
CashPaidForLeasesIncludedInOperatingCashOutflows
345000
elym Cash Paid For Leases Included In Operating Cash Outflows
CashPaidForLeasesIncludedInOperatingCashOutflows
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
915000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Organization</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Eliem Therapeutics, Inc. (the Company) is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in neuropsychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. Headquartered in Redmond, Washington, the Company was incorporated on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 18, 2018</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as a Delaware corporation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-10-18
CY2022Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
152800000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-113100000
CY2022Q3 elym Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
129600000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Key management estimates include those related to the accrual of research and development expenses, the valuation of stock-based awards, the valuation of common stock and redeemable convertible preferred stock, and the valuation of redeemable convertible preferred stock tranche liabilities. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The three months ended as of September 30, 2022 included a reversal of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of clinical expenses due to actual results differing from prior quarter estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q3 elym Change In Estimate
ChangeInEstimate
1500000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and short- and long-term marketable securities. The Company’s cash is held by two financial institutions in the United States (U.S.) and two financial institutions in the U.K. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company’s deposits held in the U.S. and U.K. may exceed the Federal Depository Insurance Corporation and Financial Services Compensation Scheme, respectively, insured limits. The Company has investments in money market funds, U.S. government debt securities, commercial paper, and corporate bonds with high-quality accredited financial institutions.</span>
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
116387000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
145034000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
900000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
900000
CY2022Q1 elym Derecognized Deferred Rent And Other Lease Liabilities
DerecognizedDeferredRentAndOtherLeaseLiabilities
12000000
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
41933000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
64109000
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
16499000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2022Q3 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022Q3 elym Recoverable Research And Development Tax Credits
RecoverableResearchAndDevelopmentTaxCredits
5066000
CY2021Q4 elym Recoverable Research And Development Tax Credits
RecoverableResearchAndDevelopmentTaxCredits
6523000
CY2022Q3 elym Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
3033000
CY2021Q4 elym Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2906000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1898000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1491000
CY2022Q3 us-gaap Other Assets
OtherAssets
555000
CY2021Q4 us-gaap Other Assets
OtherAssets
852000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10552000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11772000
CY2022Q3 elym Accrued Payroll Expenses Current
AccruedPayrollExpensesCurrent
2149000
CY2021Q4 elym Accrued Payroll Expenses Current
AccruedPayrollExpensesCurrent
2220000
CY2022Q3 elym Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1897000
CY2021Q4 elym Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2159000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
388000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
248000
CY2022Q3 elym Accrued Liabilities Current Including Related Party Transactions
AccruedLiabilitiesCurrentIncludingRelatedPartyTransactions
4434000
CY2021Q4 elym Accrued Liabilities Current Including Related Party Transactions
AccruedLiabilitiesCurrentIncludingRelatedPartyTransactions
4627000
CY2020Q4 elym Redeemable Convertible Preferred Stock Tranche Liability
RedeemableConvertiblePreferredStockTrancheLiability
551000
elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
11718000
elym Reclassification Of Redeemable Convertible Preferred Stock Tranche Liability Upon Settlement
ReclassificationOfRedeemableConvertiblePreferredStockTrancheLiabilityUponSettlement
-12269000
CY2021Q3 elym Redeemable Convertible Preferred Stock Tranche Liability
RedeemableConvertiblePreferredStockTrancheLiability
0
CY2021Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P24M
CY2021Q4 elym Operating Lease Total Office Space
OperatingLeaseTotalOfficeSpace
5000
CY2021Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P39M
CY2021Q4 elym Additional Lessee Operating Lease Term Of Contract
AdditionalLesseeOperatingLeaseTermOfContract
P3Y
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M18D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2022Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2021Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2338000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
112000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
309000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
172000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
15000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
608000
CY2022Q3 elym Present Value Adjustment For Minimum Lease Commitments
PresentValueAdjustmentForMinimumLeaseCommitments
37000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
571000
elym Employees Including Executive Officers Earning Contribution
EmployeesIncludingExecutiveOfficersEarningContribution
0.15
CY2022Q3 elym Fair Market Value Common Stock Percentage
FairMarketValueCommonStockPercentage
0.85
CY2022Q3 elym Fair Market Value Common Stock Percentage
FairMarketValueCommonStockPercentage
0.85
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2922135
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.62
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M20D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
21144000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1673932
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
62646
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.18
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4533421
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.16
elym Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3
P8Y8M15D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4285000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4488421
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.13
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y8M15D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
4285000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1499959
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.25
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M7D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0169
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0303
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.49
us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
1-for-1
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-9682000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9615000
us-gaap Net Income Loss
NetIncomeLoss
-37482000
us-gaap Net Income Loss
NetIncomeLoss
-36935000
CY2022Q3 elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
0
CY2021Q3 elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
1322000
elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
0
elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
4548000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
21750
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1783000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1236000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5096000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2583000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9682000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10937000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37482000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41483000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26336029
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26336029
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15585611
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15585611
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26290868
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26290868
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7554300
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7554300
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4752731
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4752731
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3085954
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3085954

Files In Submission

Name View Source Status
0000950170-22-024611-index-headers.html Edgar Link pending
0000950170-22-024611-index.html Edgar Link pending
0000950170-22-024611.txt Edgar Link pending
0000950170-22-024611-xbrl.zip Edgar Link pending
elym-20220930.htm Edgar Link pending
elym-20220930.xsd Edgar Link pending
elym-ex31_1.htm Edgar Link pending
elym-ex31_2.htm Edgar Link pending
elym-ex32_1.htm Edgar Link pending
elym-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img156758966_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
elym-20220930_cal.xml Edgar Link unprocessable
elym-20220930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
elym-20220930_lab.xml Edgar Link unprocessable
elym-20220930_pre.xml Edgar Link unprocessable
elym-20220930_htm.xml Edgar Link completed
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending